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Polycystic ovary syndrome (PCOS) is a common endocrine and metabolic disorder in
women. Gut microbiota has been implicated to play a critical role in metabolic diseases
and may modulate the secretion of mediators of the brain–gut axis. Interaction between
gut microbiota and the endocrine and biochemical disturbances in PCOS still remains
elusive. Here, we showed an altered gut microbiota significantly correlated with PCOS
phenotype. There were 33 patients with PCOS (non-obese PCOS individuals, PN,
n = 12; obese PCOS individuals, PO, n = 21) as well as 15 control subjects (non-obese
control individuals, CN, n = 9; obese control individuals, CO, n = 6) enrolled in our
study. The plasma levels of serotonin, ghrelin, and peptide YY (PYY) were significantly
decreased in patients with PCOS compared with controls, and have a significantly
negative correlation with waist circumference and testosterone. Sequencing of the V3–
V4 region of the 16S rRNA gene in fecal samples revealed the substantial differences
of gut microbial species between the PCOS and non-obese controls. Bacterial species
were clustered into 23 co-abundance groups (CAGs) based on the SparCC correlation
coefficients of their relative abundance. The CAGs increased in PCOS, including
the bacteria belonging to Bacteroides, Escherichia/Shigella and Streptococcus, were
negatively correlated with ghrelin, and positively correlated with testosterone and BMI.
Furthermore, the CAGs that were decreased in PCOS, including the bacteria from
Akkermansia and Ruminococcaceae, showed opposite relationship with body-weight,
sex-hormone, and brain–gut peptides. In conclusion, gut microbial dysbiosis in women
with PCOS is associated with the disease phenotypes.
Keywords: gut microbiota, polycystic ovary syndrome, obesity, testosterone, ghrelin, serotonin
Abbreviations: ALT, alanine aminotransferase; AST, aspartate transaminase; Blood RT, blood routine test; BMI, body
mass index; CAG, co-abundance group; CAP, canonical analysis of principal coordinates; CN, control with non-obesity;
CO, control with obesity; FINS, fasting plasma insulin; FSH, follicular stimulating hormone; FPG, fasting plasma glucose;
GGT, γ-glutamyltransferase; HbA1c, hemoglobin A1c; HOMA-beta, homeostasis model assessment for beta cell function;
HOMA-IR, homeostasis model assessment for insulin resistance index; LH, luteinizing hormone; LPS, lipopolysaccharide;
MANOVA, multivariate analysis of variance; OTU, operational taxonomic units; P2hINS, 2h postprandial plasma insulin;
PCOS, polycystic ovary syndrome; PN, PCOS with non-obesity; PO, PCOS with obesity; PPG, 2h postprandial plasma
glucose; PYY, peptide YY; RDA, redundancy analysis; SAS, self-rating anxiety scale; SDS, self-rating depression scale; TCH,
total cholesterol; TG, triglyceride; WHR, waist hip ratio.
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INTRODUCTION
Polycystic ovary syndrome is a common heterogeneous
endocrine and chronic metabolic disease affecting 3–26% of
reproductive-aged women by applying the different diagnostic
criteria (Michelmore et al., 1999; March et al., 2010; Li et al.,
2013). Women with PCOS are faced with increased risk
of endometrial cancer, diabetes, metabolic syndrome and
cardiovascular disease in the long term (Legro et al., 1999;
Hardiman et al., 2003; Dumesic and Lobo, 2013). They
showed hyperandrogenism, hyperinsulinemia, anovulation,
and polycystic ovarian morphology (Landay et al., 2009), and
had 2.8-fold higher prevalence of obesity compared to women
without PCOS according to a recent meta-analysis (Lim et al.,
2013). Although the genetic (Vink et al., 2006), gestational
environment (Abbott et al., 1998) and lifestyle factors (Zhang J.
et al., 2015) have been suggested to involve in the development of
PCOS, the precise underlying triggers for these key biochemical
and metabolic disturbances remain largely unclear.
Since high levels of circulating insulin stimulating the ovarian
theca cells to produce androgen had been supported by various
experiments, both in vitro and in vivo (Poretsky, 1991), a
new microbiological hypothesis for the development of PCOS
suggested that dysbiosis of gut microbiota can increase the
ovaries production of androgens, and then interfere with normal
follicle development via triggering a chronic inflammatory
response and insulin resistance (Tremellen and Pearce, 2012).
Further evidence suggests that gut microbiota and its metabolites
have the ability to regulate inflammation pathway activation,
brain–gut peptide secretion and islet β-cell proliferation, thus
leading to abnormal or excessive fat accumulation, insulin
resistance and compensatory hyperinsulinemia (Vrieze et al.,
2010; Barber et al., 2015). The shifts of gut microbiota had
been observed in the letrozole-induced PCOS mouse models
(Guo et al., 2016; Kelley et al., 2016), and fecal microbiota
transplantation from the letrozole-induced PCOS mice to germ-
free mice indicated that gut microbiota also has a close
relationship with its host’s sex hormone levels, estruscycles and
ovarian morphological changes (Guo et al., 2016). In addition,
according to another mouse model experiment, female recipients
of male cecal microbiota displayed increased testosterone levels,
compared with unmanipulated females and female recipients
of female cecal micriobiota (Markle et al., 2013). On the other
hand, some mediators of the brain–gut axis, such as serotonin,
ghrelin and PYY, whose secretion were affected by gut microbiota
(Samuel et al., 2008; Yano et al., 2015; Perry et al., 2016), were
involved in appetite regulation, systemic energy homeostasis and
LH secretion (Konturek et al., 2004; Ogata et al., 2009; Jun et al.,
2015). But the experimental evidence of the relationship between
gut microbiota, mediators of the brain–gut axis and metabolic
phenotypes of PCOS in human is still absent.
In order to study the association of gut microbiota with obesity
and non-obesity in relation to PCOS, we recruited non-obese
or obese women with or without PCOS. We investigated the
composition of gut microbiota in PCOS, and how the changes
of gut microbiota correlated with the sex-hormones, brain–gut
peptides, and various other metabolic parameters. Our study
suggested an altered composition of gut microbiota of women
with PCOS from controls, and identified important bacterial
phylotypes which were associated with the clinical characteristics
of PCOS.
MATERIALS AND METHODS
Study Participants
A total of 48 premenopausal women aged 17–45 years were
enrolled from individuals who visited the department of
endocrinology or gynecology at Shanghai General Hospital
(Shanghai, China) between January 2014 and July 2014.
Diagnosis criteria for PCOS established by Chinese Medical
Association was based on Rotterdam criteria and the currently
available evidences in Han Chinese. In our study, to avoid the
confusion due to the different diagnostic criteria, each participant
had met the three features based on Rotterdam criteria and the
Chinese criteria as follows: oligo- or anovulation, clinical and/or
biochemical signs of hyperandrogenism, and polycystic ovaries
(Rotterdam Eshre/Asrm-Sponsored Pcos Consensus Workshop
Group, 2004). Women in control group had no history of
diagnosed PCOS and did not meet any of the Rotterdam
Criteria. Individuals with one of the followings were excluded
from the study: pregnancy, androgen-secreting tumors, adrenal
disorders, thyroid dysfunction, Cushing’s syndrome, smoking,
hypertension, and lipid-dysregulation. Included participants had
also no administration of hormonal medication, insulin sensitizer
or antibiotics within the preceding 3 months. After submitting
written informed consent, all participants with PCOS (n= 33) or
without PCOS (n= 15) were then stratified according to BMI into
the following four subgroups: obese PCOS patients (PO group,
n = 21), non-obese PCOS patients (PN group, n = 12), obese
controls (CO group, n = 6) and non-obese controls (CN group,
n = 9). Obesity was defined as BMI ≥ 25 kg/m2 and the non-
obesity otherwise according to the World Health Organization
(World Health Organization, 2000). The study protocol was
approved by the Human Research Ethics Committee of Shanghai
General Hospital (No. 2014KY091) ahead of procedure of
enrollment. The trial was registered in Chinese Clinical Trial
Registry with the registration number ChiCTR-TRC-14005075.
Sampling
All subjects were examined in the morning after overnight
fasting (≥8 h). 4-(2-aminoethyl)-benzenesulfonyl fluoride was
immediately added to the blood samples for enzyme-linked
immunosorbent assay (ELISA) of ghrelin at a final concentration
of 1 mg/mL. After clotting at room temperature for 30 min,
the blood samples were centrifuged at 3,000 × g for 15 min at
4◦C, and were transferred into separate tubes and acidified by
adding 5 N HCl to a final concentration of 0.05 N. The processed
serum samples were stored at −20◦C until analysis. For PYY,
blood samples were immediately added DPP-IV inhibitor and
aprotinin to a final concentration 500 KIU/mL. Fecal samples
were collected on the same day. Feces was divided into aliquots
and was frozen on dry ice immediately upon collection and stored
at−80◦C until analysis.
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Anthropometric and Metabolic
Parameters Measurements
Waist circumference was measured midway between the lower
costal margin and the iliac crest, and hip circumference at the
level of maximum extension of the buttocks. WHR was calculated
as waist circumference divided by hip circumference. BMI was
calculated as body weight in kilograms divided by body height
squared in meters.
Biochemical indexes were measured on automatic
biochemical analyzer (Beckman AU5800 Clinical Chemistry
System, Beckman Coulter, Inc., South Kraemer Boulevard, Brea,
CA, USA). HbA1c level was measured by high-performance
liquid chromatography (Bio-Rad Variant II Turbo, Bio-
Rad Laboratories, Co., Ltd, Germany). FINS, FSH, LH, and
testosterone were tested using an automated immunoassay
system (TOSOHAIA-1800ST, TOSOH Corporation, Tokyo,
Japan). The HOMA-IR and beta cell function (HOMA-beta)
were calculated using the following formula:
HOMA-IR = fasting plasma glucose (FPG) (mM) ∗ FINS
(mIU/L)/22.5; (1)
HOMA-beta = 20 ∗ FINS (mIU/l)/(FPG
(mM) − 3.5) ∗100%. (2)
Plasma serotonin, ghrelin, and PYY levels were determined
with the commercially available ELISA kit according to
manufacturer’s instructions. The kit for serotonin was purchased
from EUROIMMUNUS, Inc. (EA602/96, Mountain Lakes,
NJ, USA), and kits for ghrelin and PYY were bought from
EMD Millipore Corporation (EZGRT-89K, EZHPYYT66K,
Saint Charles, MO, USA, respectively). The intra-assay
and inter-assay coefficients of variation were <5 and <10,
respectively.
The investigation of mental psychological health was
conducted with SDS and SAS.
Fecal DNA Extraction and Sequencing
DNA extraction from each frozen fecal sample was conducted
as previously described (Godon et al., 1997). All samples were
sequenced on the Illumina Miseq platform (Illumina, Inc.,
USA) with Miseq reagent kit v3 (600-cycle) (MS-102-3033,
Illumina, USA). Sequencing library of the V3–V4 regions of the
16S rRNA gene was constructed based on the manufacturer’s
instruction (Part # 15044223 Rev. B, Illumina, USA), with
some modifications as previously published (Zhang et al.,
2016).
Statistical Analysis
Clinical Data Statistical Analysis
Statistical analyses were performed using SAS statistical
software 9.2 (SAS Institute, Inc., Cary, NC, USA). Normal
distribution of the data was calculated with the Kolmogorov–
Smirnov test. Continuous variables were expressed as
mean ± standard deviation (SD). Variables that were
not normally distributed were rank transformed before
analysis. Differences on clinical characteristics and metabolic
biomarkers were evaluated using t-test or a one-way analysis
of variance (ANOVA) for normally distributed variables or
non-parameter Wilcoxon test for non-normally distributed,
with multiple comparisons performed using SNK (Student-
Newman-Keuls) correction. Partial correlation analysis was
used to study the relationships between brain–gut peptides and
other metabolic parameters. A multiple stepwise regression
analysis was employed to identify influence factors of
brain–gut peptides, using a stepwise selection method with
a P-value of 0.15 at entry and a P-value of 0.15 at stay. All
independent variables in the multiple regression were tested
for multicollinearity. Statistical tests were based on two tailed
probability. A P-value less than 0.05 was considered statistically
significant. Power calculation was performed using PASS
software 11.
Bioinformatics and Statistical Analysis
Quality control of the raw sequencing data was performed,
as previously described (Zhang et al., 2016), to reduce
spurious OTUs. OTUs were clustered and mapped using
Uparse (Edgar, 2013) according to Uparse OTU analysis
pipeline1. Quality-filtered sequences were clustered into unique
sequences and sorted in order of decreasing abundance to
identify representative sequences, and singletons were omitted
in this step. Chimera detection was performed using UCHIME
(Edgar et al., 2011) against the Ribosomal Database Project
(RDP) classifier (Cole et al., 2013). OTUs were clustered using
a ≥97% similarity threshold. The representative sequences
of each OTU were used to generate a phylogenetic tree
using FastTree (Price et al., 2009), and were subjected to
RDP for taxonomical assignments with a bootstrap cutoff of
80%.
The sequences of all the samples were downsized to 7500
(1000 permutations) to equal the difference in sequencing depth.
The rarefaction estimates, the Shannon index, the Simpson’s
diversity index and the Chao1 index were calculated using
QIIME v1.2.1 (Caporaso et al., 2010), and the difference of
alpha-diversity was evaluated by Kruskal–Wallis test using IBM
SPSS Statistics 19. To evaluate the structural segregation of
gut microbiota between individuals with/without PCOS, we
performed CAP (Anderson and Willis, 2003) using FORTRAN
program (Anderson, 2004). And MANOVA was estimated
using MATLAB R2014a (The MathWorks, Natick, MA,
USA). Both of CAP and MANOVA analysis were calculated
based on the Bray–Curtis (Bray and Curtis, 1957) and the
UniFrac distance (Lozupone and Knight, 2005) performed by
QIIME.
To pick key OTUs that might be responsible for the
segregation, RDA was performed using the R ‘vegan’ package.
Statistical significance was assessed by Monte Carlo test with 9999
permutations.
The OTUs shared by at least 20% among all the samples
were considered as prevalent OTUs. Correlations between
prevalent OTUs were calculated using the SparCC algorithm
1http://drive5.com/usearch/manual/uparse_pipeline.html
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TABLE 1 | The clinical characteristics and metabolic profiles of all the participants.
Parameters Controls (n = 15) PCOS (n = 33)
Non-obese, n = 9 Obese, n = 6 Non-obese, n = 12 Obese, n = 21 F P adjusted for age
Age (years) 32.2 ± 5.9 33 ± 5.4 25.5 ± 4.3 29.3 ± 6.5 3.3 /
Anthropometric parameters
BMI (kg/m2) 21.9 ± 2.2b 27.5 ± 3.3a 21.6 ± 2.2b 30 ± 3.6a 46 <0.0001
Waist circumference (cm) 68.8 ± 5.7c 84.7 ± 12.3b 75 ± 7.8c 95.1 ± 9.2a 24 <0.0001
WHR 0.78 ± 0.05c 0.8 ± 0.1b 0.79 ± 0.06bc 0.92 ± 0.05a 20 <0.0001
Hirsutism score 8 ± 0b 8 ± 0b 17.5 ± 6.5a 16.6 ± 5.7a 31 <0.0001
Blood RT
Leukocyte (10ˆ9/L) 6.8 ± 2 6.4 ± 1 7.1 ± 2.1 7.3 ± 1.7 0.5 0.49
Neutrocyte (10ˆ9/L) 4.1 ± 0.8 4.1 ± 1.2 4.5 ± 2 4.6 ± 1.2 0.5 0.6638
Lymphocyte (10ˆ9/L) 2.1 ± 0.9 2.3 ± 0.6 2 ± 0.4 2.3 ± 0.7 0.4 0.7929
Sex hormones
FSH (IU/L) 5.3 ± 2.2 7 ± 0.9 7.2 ± 2.3 6.4 ± 2.5 1.6 0.2072
LH (IU/L) 7.5 ± 4.1b 11.3 ± 5.7ab 15.7 ± 8.5a 19.4 ± 31.2ab 3.2 0.0335
Testosterone (nmol/L) 0.79 ± 0.41b 1 ± 0.4b 4.5 ± 2a 5.4 ± 2.7a 14 <0.0001
LH/FSH 1.5 ± 0.7 1.6 ± 0.7 2.3 ± 1.1 2.5 ± 2 2.1 0.1117
Metabolic parameters
FPG (mmol/L) 5 ± 0.4 5.2 ± 0.4 4.7 ± 0.5 5 ± 2.1 2.7 0.0591
PPG (mmol/L) 6 ± 0.9b 5.5 ± 1b 6 ± 1.3b 8.5 ± 2.6a 8.8 0.0001
FINS (uU/mL) 11.9 ± 4a 15.6 ± 5a 5.5 ± 2.4b 14.3 ± 7.4a 11 <0.0001
P2hINS (uU/mL) 54.1 ± 31.5b 83.7 ± 52.4ab 65.5 ± 53.3b 163 ± 99.3a 7.7 0.0003
HOMA-IR 1.7 ± 1.1a 3.5 ± 1a 1.1 ± 0.5b 3.3 ± 2.1a 11 <0.0001
HOMA-beta 159.8 ± 32.7a 203.7 ± 107a 174.8 ± 284.2a 339.8 ± 254.8a 3.3 0.0279
HbA1c (%) 5 ± 0.3b 5.3 ± 0.3b 5.2 ± 0.3b 5.9 ± 1.1a 9.4 <0.0001
ALT (U/L) 14 ± 9.6b 16.2 ± 10.7b 17.5 ± 8.9ab 32.9 ± 28.3a 4.1 0.0123
AST (U/L) 15.9 ± 1.9 16.5 ± 5.4 19.4 ± 5.5 27.7 ± 23.6 2.1 0.1198
GGT (U/L) 14.1 ± 3.6b 19.2 ± 10.4ab 13.8 ± 3.4b 26.3 ± 23.6a 4.8 0.0057
TCH (mmol/L) 4.5 ± 0.9 4.8 ± 0.9 4.4 ± 1.1 4.6 ± 0.7 0.2 0.8762
TG (mmol/L) 1 ± 0.6b 1.3 ± 1ab 0.83 ± 0.38b 1.5 ± 0.7a 7.1 0.0005
Mediators of the brain–gut axis
Serotonin (ng/mL) 294.2 ± 91.8a 199.6 ± 38.1b 211.5 ± 69b 193.6 ± 54.4b 4.1 0.012
Ghrelin (ng/mL) 0.51 ± 0.08a 0.44 ± 0.04ab 0.4 ± 0.1b 0.24 ± 0.05c 27 <0.0001
PYY (pg/mL) 79.8 ± 24.1a 79.2 ± 17.5a 56.8 ± 16.1ab 62.1 ± 48.4b 4.9 0.0052
Psychological scales
SDS value 39.2 ± 8.1b 42.4 ± 12.4ab 36.9 ± 6.9b 50.1 ± 9.4a 6.6 0.0009
SAS value 32.7 ± 5.5b 34.2 ± 7.2ab 35.9 ± 4.5ab 42.8 ± 9.1a 5.4 0.003
Data are presented as mean ± SD. Multiple comparison: means with the same letter (a, b, or c) are not significantly different, with different letters are significantly different
(adjusted P < 0.05). P-value by ANOVA for normally distributed variables or non-parameter Wilcoxon test for non-normally distributed. The parameters of age, waist
circumference, leukocyte, testosterone, AST, ALT, TCH, and SDS value were normally distributed. PCOS, polycystic ovary syndrome; BMI, body mass index; WHR, Waist
hip ratio; Blood RT, blood routine test; FSH, follicular stimulating hormone; LH, luteinizing hormone; FPG, fasting plasma glucose; PPG, 2h postprandial plasma glucose;
FINS, fasting plasma insulin; P2hINS, 2h postprandial plasma insulin; HOMA-IR, Homeostasis model assessment for insulin resistance index; HOMA-beta, Homeostasis
model assessment for beta cell function; HbA1c, Hemoglobin A1c; ALT, alanine aminotransferase; AST, aspartate transaminase; GGT, γ-glutamyltransferase; TCH, total
cholesterol; TG, triglyceride; PYY, peptide YY; SDS, self-rating depression scale; SAS, self-rating anxiety scale.
(Friedman and Alm, 2012) based on their abundance. The
correlation values were converted to a correlation distance
(1-correlation value), and the OTUs were clustered using
the Ward clustering algorithm via MATLAB. Permutational
MANOVA was used to determine CAGs via dividing the
cluster tree (9999 permutations, P < 0.001). Permutational
MANOVA was performed using the R ‘vegan’ package2 and
the CAG network was visualized in Cytoscape. Spearman
2http://www.r-project.org/
correlation between CAGs and clinical parameters was
calculated using MATLAB, and Benjamini-Hochberg
method was used to control false discovery rate (Benjamini
and Hochberg, 1995). Kruskal–Wallis test was performed
for comparing the difference of relative abundance at
CAG level between the four groups using IBM SPSS
Statistics 19.
Raw sequencing data of the 16S rRNA gene V3–V4 regions
and accompanying information are available in Sequence Read
Archive database under accession number SRP085887.
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RESULTS
General Anthropometric and Metabolic
Parameters of All the Participants
The clinical data of all the 48 participants was summarized in
Table 1. After adjusted P value for age, the differences between
groups reflected in the following aspects: anthropometric
parameters, sex hormones, metabolic parameters, mediators
of the brain–gut axis and psychological scales. Compared to
women without PCOS, women with PCOS showed significantly
higher levels of testosterone and hirsutism score. PO group also
had increased levels of metabolic parameters and SDS value
than PN group, indicating that excess weight aggravated the
metabolic abnormalities in women with PCOS. The level of
serotonin was significantly higher in CN group than the other
three groups. The level of ghrelin was lower in women with
PCOS compared with women without PCOS, and it was also
lower in obese women with PCOS compared with non-obese
women with PCOS. PYY showed a significant decrease in PO
group compared with CN and CO groups, while PN group
was also decreased compared to CN and CO and it was higher
than the PO group. Both PCOS patients and obese individuals
possessed abnormal levels of the mediators of the brain–gut
axis.
In order to evaluate the association between the mediators of
the brain–gut axis and the various metabolic characteristics
of PCOS, we calculated the partial correlation between
serotonin, PYY, ghrelin and the clinical parameters of all
subjects after adjusting for age and BMI (Table 2). Plasma
serotonin level was significantly negatively correlated with waist
TABLE 2 | Partial correlations between the brain–gut peptide/indole levels and various clinical parameters after adjusted for age and BMI.
Parameters Serotonin PYY Ghrelin
r P r P r P
Anthropometric parameters
Waist circumference −0.331 0.025 −0.507 0.000 −0.297 0.045
WHR −0.279 0.061 −0.379 0.010 −0.336 0.023
Hirsutism score −0.340 0.026 −0.421 0.005 −0.381 0.012
Blood RT
Leukocyte count 0.265 0.082 0.164 0.287 −0.008 0.959
Neutrocyte count 0.322 0.033 0.350 0.020 −0.062 0.689
Lymphocyte count 0.205 0.181 0.028 0.856 0.059 0.706
Sex hormones
FSH 0.053 0.726 0.237 0.113 −0.072 0.636
LH −0.127 0.399 −0.136 0.369 −0.222 0.139
Testosterone −0.312 0.035 −0.371 0.011 −0.627 <0.0001
LH/FSH −0.221 0.140 −0.255 0.087 −0.187 0.213
Metabolic parameters
FPG −0.157 0.298 −0.065 0.669 −0.012 0.939
PPG −0.047 0.757 −0.396 0.007 −0.418 0.004
FINS 0.173 0.251 0.083 0.583 0.086 0.568
P2hINS 0.062 0.682 −0.024 0.874 −0.338 0.022
HOMA-beta 0.351 0.017 0.317 0.032 0.157 0.298
HbA1c 0.024 0.874 −0.164 0.276 −0.111 0.462
ALT 0.014 0.926 −0.291 0.050 −0.418 0.004
AST 0.042 0.784 −0.303 0.041 −0.301 0.042
TCH 0.312 0.035 −0.156 0.299 −0.061 0.688
TG 0.115 0.447 −0.253 0.090 −0.186 0.215
Mediators of the brain–gut axis
Serotonin 1.000 / 0.282 0.058 0.215 0.151
Ghrelin 0.215 0.151 0.238 0.112 1.000 /
PYY 0.282 0.058 1.000 / 0.238 0.112
Psychological scales
SDS value −0.185 0.219 −0.135 0.370 −0.034 0.825
SAS value −0.355 0.016 −0.231 0.122 −0.064 0.671
After taking account of age and BMI, bold values indicate statistical significance determined by Spearman partial correlation analysis. BMI, body mass index; WHR, Waist
hip ratio; Blood RT, blood routine test; FSH, follicular stimulating hormone; LH, luteinizing hormone; FPG, fasting plasma glucose; PPG, 2h postprandial plasma glucose;
FINS, fasting plasma insulin; P2hINS, 2h postprandial plasma insulin; HOMA-beta, homeostasis model assessment for beta cell function; HbA1c, hemoglobin A1c; ALT,
alanine aminotransferase; AST, aspartate transaminase; TCH, total cholesterol; TG, triglyceride; PYY, peptide YY; SDS, self-rating depression scale; SAS, self-rating anxiety
scale; CN, control with non-obesity; CO, control with obesity; PN, PCOS with non-obesity; PO, PCOS with obesity.
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circumference, hirsutism score, testosterone and SAS value,
whereas, significantly positively correlated with neutrocyte
count, HOMA-beta and TCH. Plasma PYY level was significantly
negatively correlated with waist circumference, WHR, hirsutism
score, testosterone, PPG, ALT and AST, whereas, significantly
positively correlated with neutrocyte count and HOMA-beta.
Plasma ghrelin level was significantly negatively correlated
with waist circumference, WHR, hirsutism score, testosterone,
PPG, P2hINS, ALT, and AST. To explore whether plasma
brain–gut peptide/indole levels were independently associated
with the clinical parameters, multiple stepwise regression
analysis involving all the parameters with significant correlations
with the mediators of the brain–gut axis was performed (with
sle = 0.15, and sls = 0.15). Adjusting for age and BMI, it
revealed that the testosterone level (β, −2.5296; P < 0.001),
neutrocyte count (β, 0.38753; P < 0.01) and waist circumference
(β, −0.29091; P < 0.05) were independently associated with
plasma serotonin levels; the waist circumference (β, −0.27497;
P < 0.05), the PCOS group (β, −9.447; P < 0.05) and neutrocyte
count (β, 0.41872; P < 0.01) were independently associated with
plasma PYY levels; while the testosterone level (β, −1.3728;
P < 0.05), the PCOS group (β, −12.6121; P < 0.001), BMI
(β, −0.889; P < 0.01), and P2hINS (β, −0.3382; P < 0.01)
were independently associated with plasma ghrelin levels in
all participants. Thus, the levels of the brain–gut peptides and
the brain–gut indole were correlated with the PCOS related
phenotypes.
Dysbiosis of Gut Microbiota in Women
with PCOS
We performed gene sequencing on the V3–V4 regions of the
16S rRNA to evaluate the dysbiosis of gut microbiota in PCOS.
In total, 852,886 usable raw reads (264,105 unique sequences)
were obtained from all 48 samples. 770,892 high-quality reads
(14,480 ± 4,325 reads per sample) were clustered into 567
OTUs at 97% similarity level. According to observed OTUs
and the Chao1 index, CN group owned the highest richness,
followed by CO and PN group, and PO group showed
the lowest richness of gut microbiota (Figures 1A,B), while
no difference was found for the Shannon index and the
Simpson’s diversity index. CAP and MANOVA based on the
Bray–Curtis distance revealed a separation between CN group
FIGURE 1 | Overall structural differentiation of gut microbiota based on UniFrac distance between four groups. (A) OTU-level rarefaction (observed
OTUs). (B) Chao 1 index. Values are shown by box-plot. Box represents the interquartile range. The line inside the box represents the median. And whiskers denote
the minimum and maximum value. ∗∗Adjusted P < 0.01 (Kruskal–Wallis test). (C) Bray–Curtis CAP using the first 13 PCs (accounting for 80.67% of the total
variation). (D) Clustering of gut microbiota based on Bray–Curtis distance calculated with MANOVA using the first 13 PCs. ∗∗P < 0.01. CN: non-obese control
group, n = 9. CO: obese control group, n = 6. PN: non-obese PCOS group, n = 12. PO: obese PCOS group, n = 21.
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FIGURE 2 | The 28 key OTUs selected by RDA responding to PCOS or obesity. PCOS and obesity were conducted as environmental variables. Relative
abundances (after log transformation) of all OTUs were used as response variables, and responding OTUs that had at least 20% of the variability explained by all
canonical axes were selected and exhibited by black arrows. Statistical significance was assessed by Monte Carlo test with 9999 permutations.
and the other three groups (Figures 1C,D). Notably, the
gut microbiota composition of CO group was more similar
with that of PN and PO groups, rather than CN group.
CAP and MANOVA based on the UniFrac distance also
showed similar trends (Supplementary Figure S1). Thus, the
overall composition of the gut microbiota was disrupted in
PCOS.
We then used RDA to identify the gut bacteria responding
to PCOS and obesity. RDA confirmed that both PCOS and
obesity were significantly correlated to the dysbiosis of gut
microbiota (Monte Carlo Permutation Procedure, P = 0.0002
and 0.0490, respectively). We identified 28 key OTUs that
responded to the differentiation between the four groups
according to RDA (Figure 2). OTU4 belonging to genus
Bacteroides was enriched in PO group than CN and CO
groups (P < 0.01 and P < 0.05, respectively), with PN group
falling in between them. The average relative abundances
of 21 OTUs were higher in CN group than PO group
(P < 0.05), which mostly belonged to the genera Akkermansia,
Bacteroides, Clostridium IV, Lactobacillus, Oscillibacter, or
unclassified genera from family Ruminococcaceae, while
in CO and PN groups, the abundances of these OTUs
were lower than CN group but were higher than PO
group. Five OTUs were enriched in CO group, which
belonged to the genera Collinsella, Paraprevotella, Slackia,
and unclassified genera from class Clostridia and kingdom
Bacteria. OTU7 belonging to Bacteroides showed decreased
abundance in CO group, compared with the other three groups
(Figure 3).
Association between Gut Microbiota and
Clinical Parameters in PCOS and Control
Subjects
As the bacteria act as interdependent functional groups (guilds)
in the gut ecosystem (Zhang C. et al., 2015), we constructed
a co-abundance network at OTU level. There were 225 OTUs
shared by at least 20% of the samples were clustered into 23
CAGs based on SparCC correlation coefficients (Figure 4A
and Supplementary Table S1). The results showed bacteria
species in the same genus could have different response
to the environment perturbations. For example, OTU5, 86,
506, 393, 491, and 336 belonging to genus Blautia were
divided into CAG1 (both OTU5 and 506), 3, 15, 22, and 23,
respectively. According to the Kruskal–Wallis test, 14 CAGs
showed no significant difference between the four groups.
CAG1, 4, and 7 were enriched in PO group rather than
CN group. CAG 1 contained 14 OTUs, which belonged to
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FIGURE 3 | Heat map of the relative abundances of 28 key OTUs related to the alteration of gut microbiota between the four groups. The color of the
spots represents the relative abundance (normalized and log-transformed) of the OTUs. OTUs are ordered by spearman correlation analysis based on relative
abundance. The genus-level taxonomic assignment is shown on the right. For CN, n = 9; for PN, n = 12; for CO, n = 6; and for PO, n = 21.
genera Bacteroides, Escherichia/Shigella, Streptococcus, Blautia,
and Parabacteroides. CAG4 contained 5 OTUs, which mainly
belonged to Clostridium XlVa, Alistipes and Weissella. CAG7
contained OTUs belonging to Granulicatella, Streptococcus,
Peptostreptococcus, and Rothia. While, CAG10, 11, 12, and 13
decreased in PO group rather than CN group. The dominant
OTUs in CAG10-13 mostly belonged to Akkermansia, Alistipes,
Coprococcus, and Ruminococcus. In CO and PN groups, the
relative abundances of all these above CAGs fell in between
those in PO and CN groups. In addition, CAG17 and 18 showed
increased trends in CO group compared with the other groups
(Figure 4B).
To explore the relationship between gut microbiota and
host phenotype, Spearman correlation between 27 clinical
parameters and 9 CAGs that showed significant difference
among the four groups (Figure 5). The results showed
significant correlation between gut microbiota and PCOS related
symptoms, including obesity, inflammation, hyperinsulinmia,
hyperandrogenism, abnormal ghrelin level, and psychological
state. CAG1, 4 and 7, which were enriched in PO group,
had a positive correlation with the disease phenotypes; while
CAG10–13 and 18, which were enriched in CN group, had an
opposite trend.
DISCUSSION
Our current study showed a broad view of the association
between PCOS and gut microbiota in human. Our study, to the
best of our knowledge, is the first clinical study that revealed
the overall composition of gut microbiota in women with PCOS.
In this study, we observed an altered gut microbial pattern
in both obese and non-obese women with PCOS against non-
obese control individuals, and found that the gut microbiota
of PCOS shares similar compositional dysbiosis with that of
obesity. Furthermore, the altered gut microbiota of PCOS was
associated with the metabolic parameters, the sex-hormones and
the mediators of the brain–gut axis.
Polycystic ovary syndrome leads to several complications,
which include hyperandrogenism, obesity, and metabolic
syndrome. In the current work, compared to women with
obesity or PCOS alone, obese women with PCOS had more
deleterious metabolic disorder, including insulin resistance and
dyslipidemia, in accord with previous studies (Lim et al., 2013;
Behboudigandevani et al., 2016). Based on our data, changes
of gut microbiota also had trends similar to the variations
of metabolic symptoms. Women with obesity and PCOS
shared similar dysbiosis of gut microbiota. When compared
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FIGURE 4 | Bacterial correlation based on relative abundance in women with or without PCOS. (A) Co-abundance groups interaction network. Network
shows correlation relationships between 23 CAGs of 225 OTUs from all samples. Node size represents the average abundance of each OTU. Lines between nodes
represent correlations of each other, with the line width representing the correlation magnitude. The red ones represent positive correlations, and the blue ones
represent negative correlations. Only lines whose absolute value of correlation coefficient greater than 0.50 are drawn, and unconnected nodes are omitted.
(B) Group-level abundance differentiation of CAGs. Data are visualized by box-plot. Box represents the interquartile range. The line inside the box represents the
median. And whiskers denote the minimum and maximum value. ∗adjusted P < 0.05, ∗∗adjusted P < 0.01, and ∗∗∗adjusted P < 0.001 (multiple comparisons of
Kruskal–Wallis test). For CN, n = 9; For PN, n = 12; For CO, n = 6; For PO, n = 21.
with women with obesity or PCOS alone, obese women with
PCOS possessed a more serious dysbiosis of gut microbiota.
We observed that some gram-negative bacteria belonging to
the genera Bacteroides and Escherichia/Shigella significantly
increased in the gut of PCOS women with obesity. Bacterial LPS
produced by gram-negative bacteria has been demonstrate to
induce chronic inflammation, obesity, and insulin resistance in
LPS-infused mice (Cani et al., 2007). While various experiments,
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FIGURE 5 | Associations between clinical parameters and gut microbiota. The color of spots represents R value of Spearman correlation between each CAG
and clinical parameter. +FDR < 0.05, ++FDR < 0.01. For leucocyte, neutrocyte, lymphocyte and hirsutism, n = 46; for the other parameters, n = 48. BMI, body
mass index; WHR, Waist hip ratio; Blood RT, blood routine test; FSH, follicular stimulating hormone; LH, luteinizing hormone; FPG, fasting plasma glucose; PPG, 2h
postprandial plasma glucose; FINS, fasting plasma insulin; P2hINS, 2h postprandial plasma insulin; HOMA-IR, homeostasis model assessment for insulin resistance
index; HOMA-beta, homeostasis model assessment for beta cell function; HbA1c, hemoglobin A1c; ALT, alanine aminotransferase; AST, aspartate transaminase;
GGT, γ-glutamyltransferase; TCH, total cholesterol; TG, triglyceride; PYY, peptide YY; SDS, self-rating depression scale; SAS, self-rating anxiety scale.
both in vitro and in vivo, have verified that high levels of
circulating insulin stimulates the ovarian theca cells to produce
androgen (Poretsky, 1991). It suggests that gut microbiota
antigen might also associate to the metabolic disorder in PCOS.
On the contrary, we found that Akkermensia decreased in
obesity and PCOS, which can restore host mucus layer and has
been considered to contribute to the reduction in metabolic
endotoxemia (Everard et al., 2013). Hence, the dysbiosis of gut
microbiota, as increasing LPS-producing bacteria and decreasing
protective bacteria, may correlate with the development of
metabolic disorder in PCOS.
Some mediators of the brain–gut axis, such as serotonin and
ghrelin were involved in appetite regulation (Konturek et al.,
2004; Jun et al., 2015) as well as psychological well-being in PCOS
(Lang et al., 2015). Moreover, intracerebroventricular injection
of ghrelin significantly reduced serum LH level and pulsatile
frequency in rats (Ogata et al., 2009). However, the relationship
between the levels of serum mediators of the brain–gut axis
and PCOS remains controversial in human studies. For example,
the ghrelin level had significant difference between PCOS and
BMI-matched controls in a Spanish study (Micic et al., 2007),
but this orexigenic hormone showed association only with body
weight in an Australian PCOS cohort (Samantha et al., 2014). The
fasting PYY level also had conflicting results from different cohort
(Zwirska-Korczala et al., 2008; Lin et al., 2015). Our study showed
that women with PCOS had a significant decrease of serotonin,
ghrelin, and PYY level compared with controls, and obesity
enhanced the difference of serotonin and ghrelin in PCOS.
Moreover, we find that the levels of serotonin, PYY, and ghrelin
had a negative correlation with PCOS related parameters, such as
waist circumference and testosterone. Our results indicated that
the mediators of the brain–gut axis are associated with PCOS.
The secretion of some mediators of the brain–gut axis is
regulated by gut microbiota. It has been shown that serotonin
biosynthesis is promoted by spore-forming bacteria isolated from
the mouse and human gut microbiota, known to be dominated by
Clostridial species, while species belonging to Bacteroides didn’t
show this function (Yano et al., 2015). In our study, most of the
decreased key OTUs were Clostridial species, and the increased
key OTU was Bacteroides spp. in both PCOS and obesity cohorts.
PYY secretion is influenced by short chain fatty acid (SCFA)
produced by gut microbiota (Tremaroli and Bäckhed, 2012). In
the current, we also found the association between ghrelin and
gut microbiota. For example, CAG1, which includes Bacteroides,
Escherichia/Shigella and Blautia, was negatively correlated with
ghrelin, while CAG10, including Akkermansia, was positively
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correlated with ghrelin. But we did not find a significant
association between serotonin, PYY and the gut microbiota,
which might be explained by the limitation of small sample size
and require further studies. Regardless, according to existing
evidences, regulating the mediators of the brain–gut axis might
be one of the pathways for gut microbiota to effect on
PCOS.
This cross-sectional study revealed the association between
gut microbiota and PCOS. The dysbiosis of gut microbiota
might contribute to the development of PCOS through the
possible mechanisms discussed above. Due to the limited
sample size (power calculation: the power values for BMI, waist
circumference, testosterone level and fasting insulin level were
99.0, 96.9, 89.5, and 70.4% respectively, α = 0.0083) and the
observation of association but not causality, further studies are
needed to enlarge sample size and explore the potential causal
mechanisms between gut microbiota and PCOS, such as the
metabolites produced by gut microbiota and fecal microbiota
transplantation.
Taken together, our work suggested an altered composition of
gut microbiota, represented by the reduction of alpha diversity,
the increase of LPS-producing bacteria, and the decrease of spore-
forming species. This study also demonstrated the association
between gut microbiota and PCOS-related clinical parameters.
The previous study did not find any association of the saliva
microbiota and PCOS phenotypes (Lindheim et al., 2016),
indicating that the gut microbiota has a closer relationship with
PCOS. It laid a foundation of research on the interaction between
gut microbiota and its host with PCOS.
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